{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:13:50Z","timestamp":1770970430545,"version":"3.50.1"},"reference-count":113,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["RF 2018-12365391"],"award-info":[{"award-number":["RF 2018-12365391"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Palmitoylethanolamide (PEA) stands out among endogenous lipid mediators for its neuroprotective, anti-inflammatory, and analgesic functions. PEA belonging to the N-acetylanolamine class of phospholipids was first isolated from soy lecithin, egg yolk, and peanut flour. It is currently used for the treatment of different types of neuropathic pain, such as fibromyalgia, osteoarthritis, carpal tunnel syndrome, and many other conditions. The properties of PEA, especially of its micronized or ultra-micronized forms maximizing bioavailability and efficacy, have sparked a series of innovative research to evaluate its possible application as therapeutic agent for neurodegenerative diseases. Neurodegenerative diseases are widespread throughout the world, and although they are numerous and different, they share common patterns of conditions that result from progressive damage to the brain areas involved in mobility, muscle coordination and strength, mood, and cognition. The present review is aimed at illustrating in vitro and in vivo research, as well as human studies, using PEA treatment, alone or in combination with other compounds, in the presence of neurodegeneration. Namely, attention has been paid to the effects of PEA in counteracting neuroinflammatory conditions and in slowing down the progression of diseases, such as Alzheimer\u2019s disease, Parkinson\u2019s disease, Huntington\u2019s disease, Frontotemporal dementia, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis. Literature research demonstrated the efficacy of PEA in addressing the damage typical of major neurodegenerative diseases.<\/jats:p>","DOI":"10.3390\/biom12050667","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T13:10:26Z","timestamp":1651756226000},"page":"667","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-4425","authenticated-orcid":false,"given":"Eugenia","family":"Landolfo","sequence":"first","affiliation":[{"name":"Fondazione Santa Lucia IRCCS, 00143 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Cutuli","sequence":"additional","affiliation":[{"name":"Fondazione Santa Lucia IRCCS, 00143 Rome, Italy"},{"name":"Department of Psychology, University of Rome \u201cSapienza\u201d, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-5168","authenticated-orcid":false,"given":"Laura","family":"Petrosini","sequence":"additional","affiliation":[{"name":"Fondazione Santa Lucia IRCCS, 00143 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Caltagirone","sequence":"additional","affiliation":[{"name":"Fondazione Santa Lucia IRCCS, 00143 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Peritore, A.F., Siracusa, R., Crupi, R., and Cuzzocrea, S. (2019). Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets. Nutrients, 11.","DOI":"10.3390\/nu11092175"},{"key":"ref_2","first-page":"5716","article-title":"Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes","volume":"32","author":"Leuti","year":"2018","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.001","article-title":"New players in the fatty acyl ethanolamide metabolism","volume":"86","author":"Rahman","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/bjp.2008.324","article-title":"\u2018Entourage\u2019 effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors","volume":"155","author":"Ho","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1038\/s41598-017-07519-8","article-title":"A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum","volume":"7","author":"Musella","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bjp.0704900","article-title":"Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: Inhibition of nitric oxide and cyclo\u2013oxygenase systems","volume":"137","author":"Costa","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3389\/fphys.2017.00902","article-title":"Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications","volume":"8","author":"Carta","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_8","first-page":"151028","article-title":"Palmitoylethanolamide: A Natural Body\u2013Own Anti\u2013Inflammatory Agent, Effective and Safe against Influenza and Common Cold","volume":"2013","author":"Witkamp","year":"2013","journal-title":"Int. J. Inflam."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/fsn3.392","article-title":"Safety of micronized palmitoylethanolamide (microPEA): Lack of toxicity and genotoxic potential","volume":"5","author":"Nestmann","year":"2016","journal-title":"Food Sci. Nutr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.13020","article-title":"Palmitoylethanolamide for the treatment of pain: Pharmacokinetics, safety and efficacy","volume":"82","author":"Gabrielsson","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/bph.13580","article-title":"The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations","volume":"174","author":"Petrosino","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Petrosino, S., and Schiano Moriello, A. (2020). Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries\u2013A Systematic Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249526"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1398-9995.2009.02254.x","article-title":"Protective role of palmitoylethanolamide in contact allergic dermatitis","volume":"65","author":"Petrosino","year":"2010","journal-title":"Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41232-018-0086-5","article-title":"Endocannabinoids and related N-acylethanolamines: Biological activities and metabolism","volume":"38","author":"Tsuboi","year":"2018","journal-title":"Inflamm. Regener."},{"key":"ref_15","first-page":"237","article-title":"Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma","volume":"13","author":"Esposito","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.phrs.2014.05.006","article-title":"Palmitoylethanolamide in CNS health and disease","volume":"86","author":"Russo","year":"2014","journal-title":"Pharmacol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fncel.2018.00072","article-title":"An Inflammation\u2013Centric View of Neurological Disease: Beyond the Neuron","volume":"12","author":"Skaper","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20966","DOI":"10.1073\/pnas.0907417106","article-title":"Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation","volume":"106","author":"Solorzano","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1871527311312010005","article-title":"Biosynthetic pathways of bioactive N\u2013acylethanolamines in brain","volume":"12","author":"Tsuboi","year":"2013","journal-title":"CNS Neurol. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rankin, L., and Fowler, C.J. (2020). The Basal Pharmacology of Palmitoylethanolamide. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217942"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"C145","DOI":"10.1007\/BF01972748","article-title":"A proposed autacoid mechanism controlling mastocyte behaviour","volume":"39","author":"Aloe","year":"1993","journal-title":"Agents Actions"},{"key":"ref_22","first-page":"1486010","article-title":"Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome","volume":"2017","author":"Paladini","year":"2017","journal-title":"Pain Res. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fphar.2017.00857","article-title":"Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse","volume":"8","author":"Roviezzo","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjp.0704466","article-title":"Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat","volume":"135","author":"Conti","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Saturnino, C., Popolo, A., Ramunno, A., Adesso, S., Pecoraro, M., Plutino, M.R., Rizzato, S., Albinati, A., Marzocco, S., and Sala, M. (2017). Anti-Inflammatory, Antioxidant and Crystallographic Studies of N-Palmitoyl-ethanol Amine (PEA) Derivatives. Molecules, 22.","DOI":"10.3390\/molecules22040616"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"27618","DOI":"10.1038\/srep27618","article-title":"Localization of PPAR isotypes in the adult mouse and human brain","volume":"6","author":"Warden","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13041-017-0318-7","article-title":"The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress","volume":"10","author":"Shi","year":"2017","journal-title":"Mol. Brain"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, R., Impellizzeri, D., Cuzzocrea, S., and Di Paola, R. (2020). ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155330"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3389\/fphar.2019.00821","article-title":"Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer\u2019s Disease","volume":"10","author":"Beggiato","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ardizzone, A., Fusco, R., Casili, G., Lanza, M., Impellizzeri, D., Esposito, E., and Cuzzocrea, S. (2021). Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041967"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-014-0136-0","article-title":"Micronized\/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain","volume":"11","author":"Impellizzeri","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Noce, A., Albanese, M., Marrone, G., Di Lauro, M., Pietroboni Zaitseva, A., Palazzetti, D., Guerriero, C., Paolino, A., Pizzenti, G., and Di Daniele, F. (2021). Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. Pharmaceuticals, 14.","DOI":"10.3390\/ph14040336"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cordaro, M., Cuzzocrea, S., and Crupi, R. (2020). An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events. Antioxidants, 9.","DOI":"10.3390\/antiox9030216"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12031-018-1094-2","article-title":"The flavone luteolin improves central nervous system disorders by different mechanisms: A review","volume":"65","author":"Ashaari","year":"2018","journal-title":"J. Mol. Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.supflu.2018.07.020","article-title":"Production of PEA composite microparticles with polyvinylpyrrolidone and luteolin using supercritical assisted atomization","volume":"143","author":"Adami","year":"2019","journal-title":"J. Supercrit. Fluids."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev-food-030216-030125","article-title":"The Role of Nutrition for the Aging Population: Implications for Cognition and Alzheimer\u2019s Disease","volume":"10","author":"Power","year":"2019","journal-title":"Annu. Rev. Food Sci. Technol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.arr.2016.09.010","article-title":"Nutrition for the ageing brain: Towards evidence for an optimal diet","volume":"35","author":"Vauzour","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"683459","DOI":"10.3389\/fcell.2021.683459","article-title":"The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration","volume":"9","author":"Azam","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12035-017-0722-0","article-title":"Co\u2013Ultramicronized Palmitoylethanolamide\/Luteolin Facilitates the Development of Differentiating and Undifferentiated Rat Oligodendrocyte Progenitor Cells","volume":"55","author":"Skaper","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fncel.2017.00024","article-title":"Glial Cells and Their Function in the Adult Brain: A Journey through the History of Their Ablation","volume":"11","author":"Jakel","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hussain, R., Zubair, H., Pursell, S., and Shahab, M. (2018). Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. Brain Sci., 8.","DOI":"10.3390\/brainsci8090177"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"a028035","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of Neurodegenerative Diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1212\/WNL.64.12_suppl_3.S34","article-title":"Diagnosis and treatment of Alzheimer\u2019s disease","volume":"64","author":"Desai","year":"2005","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson\u2019s disease: Dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C.E., and Ben-Shlomo, Y. (2011). Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson\u2019s disease: Evidence from observational studies. Cochrane Database Syst Rev., Cd008454.","DOI":"10.1002\/14651858.CD008454.pub2"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s40520-016-0533-6","article-title":"PEALut efficacy in mild cognitive impairment: Evidence from a SPECT case study!","volume":"28","author":"Naro","year":"2016","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2174\/1871527316666170321124949","article-title":"Ultra\u2013micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson\u2019s Disease","volume":"16","author":"Brotini","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_49","first-page":"12","article-title":"Palmitoylethanolamide\/Luteolin as Adjuvant Therapy to Improve an Unusual Case of Camptocormia in a Patient with Parkinson\u2019s Disease: A Case Report","volume":"18","author":"Brotini","year":"2021","journal-title":"Innov. Clin. Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3233\/JAD-200426","article-title":"Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal Dementia","volume":"76","author":"Assogna","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2174\/1871527311201070933","article-title":"Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: A case report","volume":"11","author":"Clemente","year":"2012","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1073\/pnas.1600251113","article-title":"Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy","volume":"113","author":"Palma","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jns.2009.07.021","article-title":"Plasma endocannabinoid levels in multiple sclerosis","volume":"287","author":"Feng","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/acupmed-2011-010119","article-title":"Multimodal stepped care approach with acupuncture and PPAR\u2013\u03b1 agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain","volume":"30","author":"Kopsky","year":"2012","journal-title":"Acupunct. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s13311-016-0420-z","article-title":"Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon\u2013\u03b21a and Circulating Proinflammatory Cytokines in Relapsing\u2013Remitting Multiple Sclerosis","volume":"13","author":"Orefice","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/1871527318666190131121827","article-title":"Short\u2013Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: A Pilot Study to Possible Future Implications of Treatment","volume":"18","author":"Onesti","year":"2019","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e1419","DOI":"10.1038\/cddis.2014.376","article-title":"Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer\u2019s disease","volume":"5","author":"Scuderi","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/npp.2012.25","article-title":"Palmitoylethanolamide protects against the amyloid\u2013\u03b225\u201335\u2013induced learning and memory impairment in mice, an experimental model of Alzheimer disease","volume":"37","author":"Russo","year":"2012","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4720532","DOI":"10.1155\/2018\/4720532","article-title":"Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer\u2019s Disease: In vitro and In vivo Evidence","volume":"2018","author":"Bronzuoli","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41398-017-0076-4","article-title":"Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer\u2019s disease by exerting anti\u2013inflammatory and neuroprotective effects","volume":"8","author":"Scuderi","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Beggiato, S., Tomasini, M.C., Cassano, T., and Ferraro, L. (2020). Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer\u2019s Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020428"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Esposito, E., Impellizzeri, D., Mazzon, E., Paterniti, I., and Cuzzocrea, S. (2012). Neuroprotective activity of palmitoylethanolamide in an animal model of Parkinson\u2019s disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041880"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1007\/s12035-018-0959-2","article-title":"N\u2013palmitoylethanolamide prevents parkinsonian phenotypes in aged mice","volume":"55","author":"Crupi","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.phrs.2016.09.004","article-title":"Palmitoylethanolamide protects mice against 6\u2013OHDA\u2013induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence","volume":"113","author":"Avagliano","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2174\/1871527314666150821102823","article-title":"The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson\u2019s Disease Model","volume":"14","author":"Siracusa","year":"2015","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9251","DOI":"10.1007\/s12035-018-1064-2","article-title":"2\u2013Pentadecyl\u20132\u2013Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease","volume":"55","author":"Cordaro","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuint.2007.06.031","article-title":"Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6\/2 mice, a transgenic model of Huntington\u2019s disease","volume":"52","author":"Bisogno","year":"2008","journal-title":"Neurochem. Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1096\/fj.00-0399fje","article-title":"Endocannabinoids control spasticity in a multiple sclerosis model","volume":"15","author":"Baker","year":"2001","journal-title":"FASEB J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuroscience.2015.01.030","article-title":"Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL\/6 mice","volume":"290","author":"Rahimi","year":"2015","journal-title":"Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12974-019-1514-4","article-title":"A co\u2013ultramicronized palmitoylethanolamide\/luteolin composite mitigates clinical score and disease\u2013relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis","volume":"16","author":"Contarini","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1460-9568.2008.06377.x","article-title":"Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide","volume":"28","author":"Petrosino","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nbd.2019.01.007","article-title":"N\u2013Palmitoylethanolamine\u2013oxazoline (PEA\u2013OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion","volume":"125","author":"Impellizzeri","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(06)68542-5","article-title":"International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment","volume":"367","author":"Gauthier","year":"2006","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1017\/S1092852900016175","article-title":"Beyond the \u201cC\u201d in MCI: Noncognitive symptoms in amnestic and non\u2013amnestic mild cognitive impairment","volume":"13","author":"Ellison","year":"2008","journal-title":"CNS Spectr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/joim.12190","article-title":"Mild cognitive impairment: A concept in evolution","volume":"275","author":"Petersen","year":"2014","journal-title":"Int. J. Med."},{"key":"ref_76","first-page":"CD009628","article-title":"Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer\u2019s disease in people with mild cognitive impairment","volume":"3","author":"Lombardi","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_77","first-page":"a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Frosch","year":"2011","journal-title":"Cold Spring Cold Spring Harb. Perspect. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2015.10.013","article-title":"Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis","volume":"39","author":"Andrews","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s disease: Targeting the cholinergic system","volume":"14","author":"Guimaraes","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1111\/j.1582-4934.2011.01267.x","article-title":"Palmitoylethanolamide counteracts reactive astrogliosis induced by \u03b2\u2013amyloid peptide","volume":"15","author":"Scuderi","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1742-2094-9-49","article-title":"Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator\u2013activated receptor\u2013\u03b1","volume":"9","author":"Scuderi","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1871527311312010011","article-title":"Neuroglial roots of neurodegenerative diseases: Therapeutic potential of palmitoylethanolamide in models of Alzheimer\u2019s disease","volume":"12","author":"Scuderi","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-170699","article-title":"Palmitoylethanolamide blunts amyloid-\u03b242-induced astrocyte activation and improves neuronal survival in primary mouse cortical astrocyte\u2013neuron co-cultures","volume":"61","author":"Beggiato","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3233\/JAD-143039","article-title":"Differential Effects of Palmitoylethanolamide against Amyloid\u2013\u03b2 Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild\u2013Type and 3xTg\u2013AD Mice","volume":"46","author":"Tomasini","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"118037","DOI":"10.1016\/j.lfs.2020.118037","article-title":"Astrocytic palmitoylethanolamide pre\u2013exposure exerts neuroprotective effects in astrocyte\u2013neuron co\u2013cultures from a triple transgenic mouse model of Alzheimer\u2019s disease","volume":"257","author":"Beggiato","year":"2020","journal-title":"Life Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2174\/1871527313666140806124322","article-title":"Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer\u2019s disease models: The control of neuroinflammation","volume":"13","author":"Paterniti","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-0716-1712-0_7","article-title":"Biomarkers in Parkinson\u2019s Disease","volume":"Volume 173","author":"Peplow","year":"2022","journal-title":"Neurodegenerative Diseases Biomarkers"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","article-title":"Biology of Parkinson\u2019s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder","volume":"6","author":"Alexander","year":"2004","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_90","first-page":"504","article-title":"Parkinson\u2019s Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis","volume":"40","author":"DeMaagd","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","article-title":"Understanding Dopaminergic Cell Death Pathways in Parkinson Disease","volume":"90","author":"Michel","year":"2016","journal-title":"Neuron"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","article-title":"Epidemiology and etiology of Parkinson\u2019s disease: A review of the evidence","volume":"26","author":"Wirdefeldt","year":"2011","journal-title":"Eur. J. Epidemiol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Pajares, M., Rojo, A.I., Manda, G., Bosc\u00e1, L., and Cuadrado, A. (2020). Inflammation in Parkinson\u2019s Disease: Mechanisms and Therapeutic Implications. Cells, 9.","DOI":"10.3390\/cells9071687"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","article-title":"Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases","volume":"10","author":"Erkkinen","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_96","first-page":"11","article-title":"The actions of 1\u2013methyl\u20134\u2013phenyl\u20131,2,3,6\u2013tetrahydropyridine in animals as a model of Parkinson\u2019s disease","volume":"20","author":"Jenner","year":"1986","journal-title":"J. Neural Transm. Suppl."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_98","first-page":"1202","article-title":"The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size","volume":"60","author":"Brinkman","year":"1997","journal-title":"Am. J. Hum. Genet."},{"key":"ref_99","first-page":"100056","article-title":"Huntington disease: Advances in the understanding of its mechanisms","volume":"3","author":"Gatto","year":"2020","journal-title":"Clin. Park. Relat. Disord."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0278-5846(01)00162-2","article-title":"The role of cannabinoids in neurodegenerative diseases","volume":"25","author":"Glass","year":"2001","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_101","first-page":"464","article-title":"Frontotemporal Dementias","volume":"22","author":"Finger","year":"2016","journal-title":"Continuum"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2045125317739818","article-title":"Frontotemporal dementia: Latest evidence and clinical implications","volume":"8","author":"Young","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/2152-7806.169561","article-title":"A comprehensive review of amyotrophic lateral sclerosis","volume":"6","author":"Zarei","year":"2015","journal-title":"Surg. Neurol. Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","volume":"390","author":"Hardiman","year":"2017","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1212\/01.wnl.0000167602.38643.29","article-title":"A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS\/FTLD","volume":"65","author":"Chang","year":"2005","journal-title":"Neurology"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Correale, J., Marrodan, M., and Ysrraelit, M.C. (2019). Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis. Biomedicines, 7.","DOI":"10.3390\/biomedicines7010014"},{"key":"ref_108","first-page":"14","article-title":"Cognitive impairment in multiple sclerosis: A forgotten disability remembered","volume":"2012","author":"Rahn","year":"2012","journal-title":"Cerebrum"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1089\/ars.2012.5068","article-title":"Multiple sclerosis: Molecular mechanisms and therapeutic opportunities","volume":"19","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJMoa010994","article-title":"Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis","volume":"346","author":"Chang","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"16676","DOI":"10.1038\/srep16676","article-title":"Co-ultramicronized Palmitoylethanolamide\/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells","volume":"5","author":"Barbierato","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"698133","DOI":"10.3389\/fphar.2021.698133","article-title":"Co-Ultramicronized Palmitoylethanolamide\/Luteolin-Induced Oligodendrocyte Precursor Cell Differentiation is Associated with Tyro3 Receptor Upregulation","volume":"12","author":"Facci","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/5\/667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:06:13Z","timestamp":1760137573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/5\/667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":113,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["biom12050667"],"URL":"https:\/\/doi.org\/10.3390\/biom12050667","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]}}}